Bath Savings Trust Co Sells 4,433 Shares of Zoetis Inc. $ZTS

Key Points

• Bath Savings Trust Co has reduced its stake in Zoetis Inc. by 31.8% during the 2nd quarter, selling 4,433 shares, resulting in a total holding of 9,528 shares worth approximately $1.49 million.
• Analysts have mixed opinions on Zoetis, with five rating it as a Buy and four as Hold, while consensus target prices vary from $155.00 to $215.00.
• Zoetis reported earnings of $1.76 per share for the last quarter, surpassing expectations, with revenues increasing 4.2% year-over-year to $2.46 billion.

Bath Savings Trust Co reduced its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 31.8% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 9,528 shares of the company's stock after selling 4,433 shares during the quarter. Bath Savings Trust Co's holdings in Zoetis were worth $1,486,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Alecta Tjanstepension Omsesidigt grew its stake in shares of Zoetis by 24.5% during the second quarter. Alecta Tjanstepension Omsesidigt now owns 709,900 shares of the company's stock valued at $110,659,000 after buying an additional 139,500 shares during the last quarter. Secure Asset Management LLC grew its stake in shares of Zoetis by 2.9% during the second quarter. Secure Asset Management LLC now owns 2,448 shares of the company's stock valued at $382,000 after buying an additional 68 shares during the last quarter. Baader Bank Aktiengesellschaft grew its stake in shares of Zoetis by 43.5% during the second quarter. Baader Bank Aktiengesellschaft now owns 3,590 shares of the company's stock valued at $540,000 after buying an additional 1,089 shares during the last quarter. Sivia Capital Partners LLC grew its stake in shares of Zoetis by 73.8% during the second quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company's stock valued at $522,000 after buying an additional 1,422 shares during the last quarter. Finally, Sarasin & Partners LLP grew its stake in shares of Zoetis by 3.7% during the second quarter. Sarasin & Partners LLP now owns 1,611,579 shares of the company's stock valued at $251,326,000 after buying an additional 57,724 shares during the last quarter. 92.80% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ZTS. Piper Sandler raised their price objective on Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a research note on Monday, August 11th. Leerink Partners cut Zoetis from an "outperform" rating to a "market perform" rating and cut their target price for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Stifel Nicolaus cut Zoetis from a "buy" rating to a "hold" rating and cut their target price for the stock from $165.00 to $160.00 in a research note on Wednesday, June 18th. Argus reissued a "buy" rating and issued a $190.00 target price on shares of Zoetis in a research note on Tuesday, September 9th. Finally, Leerink Partnrs cut Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Five research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, Zoetis has an average rating of "Moderate Buy" and an average target price of $200.88.

Zoetis Stock Down 0.8%

ZTS traded down $1.15 on Monday, hitting $144.73. The company had a trading volume of 2,044,648 shares, compared to its average volume of 2,375,084. The stock has a fifty day simple moving average of $151.03 and a 200-day simple moving average of $156.27. Zoetis Inc. has a 52-week low of $139.70 and a 52-week high of $197.51. The firm has a market capitalization of $64.14 billion, a P/E ratio of 24.91, a P/E/G ratio of 2.34 and a beta of 0.88. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04.

Zoetis (NYSE:ZTS - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.41 billion. During the same period last year, the business earned $1.56 earnings per share. The business's revenue was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.